ArticleeLife2015
Why clinical translation cannot succeed without failure.
Article in eLife, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review.PLoS biology · 2017Pooled it
- Preclinical assessment for translation to humans: The PATH approach for assessing supporting evidence for early-phase trials and innovative care.Med (New York, N.Y.) · 2024Review
- Clinical development of new drugs for adults and children with cancer, 2010-2020.Journal of the National Cancer Institute · 2023Article
- Quantifying Patient Investment in Novel Neurological Drug Development.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Article
- Article
- Translational Block in Stroke: A Constructive and "Out-of-the-Box" Reappraisal.Frontiers in neuroscience · 2021Article
- Improving the Translational Medicine Process: Moving Patients From "End-Users" to "Engaged Collaborators".Frontiers in medicine · 2019Article
- Article
- Better to be in The Placebo Arm for Trials of Neurological Therapies?Cell transplantation · 2018Article
- Preclinical efficacy studies in investigator brochures: Do they enable risk-benefit assessment?PLoS biology · 2018Article
- High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona.Scientific reports · 2017Article
- Animal Study Registries: Results from a Stakeholder Analysis on Potential Strengths, Weaknesses, Facilitators, and Barriers.PLoS biology · 2016Article
- BVS, RDN, IABP: The Afghanistan of interventional cardiology trials.Indian heart journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high rates of attrition that occur in drug development are widely regarded as problematic, but the failure of well-designed studies benefits both researchers and healthcare systems by, for example, generating evidence about disease theories and demonstrating the limits of proven drugs. A wider recognition of these benefits will help the biomedical research enterprise to take full advantage of all the information generated during the drug development process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.